Flavia Lozzi

Flavia Lozzi

Auto-generated profile, based on publicly available information

Flavia Lozzi

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2024 in Environmental Research
Verified
Journal Article
Closed access
FAFabio Artosi
Fabio Artosi
gaetana Costanzagaetana Costanza
gaetana Costanza
MPMonia Di Prete
Monia Di Prete
VGVirginia Garofalo
Virginia Garofalo
FLFlavia Lozzi
Flavia Lozzi
Elena CampioneElena Campione
Elena Campione

23 May 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
CCClaudia Ceci
Claudia Ceci
FRFederica Ruffini
Federica Ruffini
Mattia FalconiMattia Falconi
Mattia Falconi
MAMaria Grazia Atzori
Maria Grazia Atzori
AFAndrea Falzon
Andrea Falzon
PLPedro Miguel Lacal
Pedro Miguel Lacal
Activation of neuropilin-1 (NRP-1) by platelet derived growth factor (PDGF)-C sustains melanoma invasiveness. Therefore, in the search of novel agents capable of reducing melanoma spreading, PDGF-C/NRP-1 interaction was investigated as a potential druggable target. Since the PDGF-C region involved in NRP-1 binding is not yet known, based on the sequence and structural homology between PDGF-C and vascular endothelial growth factor-A (VEGF-A), we hypothesized that the NRP-1 b1 domain region involved in the interaction with VEGF-A might also be required for PDGF-C binding. Hence, this region was selected from the protein crystal structure and used as target in the molecular docking procedure. In the following virtual screening, compounds from a DrugBank database were used as query ligands to identify agents potentially capable of disrupting NRP-1/PDGF-C interaction. Among the top 45 candidates with the highest affinity, five drugs were selected based on the safety profile, lack of hormonal effects, and current availability in the market: the antipsychotic pimozide, antidiabetic gliclazide, antiallergic cromolyn sodium, anticancer tyrosine kinase inhibitor entrectinib, and antihistamine azelastine. Analysis of drug influence on PDGF-C in vitro binding to NRP-1 and PDGF-C induced migration of human melanoma cells expressing NRP-1, indicated gliclazide and entrectinib as the most specific agents that were active at clinically achievable and non-toxic concentrations. Both drugs also reverted PDGF-C ability to stimulate extracellular matrix invasion by melanoma cells resistant to BRAF inhibitors. The inhibitory effect on tumor cell motility involved a decrease of p130Cas phosphorylation, a signal transduction pathway activated by PDGF-C-mediated stimulation of NRP-1.

1 December 2019 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
Elena CampioneElena Campione
Elena Campione
SMSara Mazzilli
Sara Mazzilli
CLCaterina Lanna
Caterina Lanna
Terenzio CosioTerenzio Cosio
Terenzio Cosio
VPVincenzo Palumbo
Vincenzo Palumbo
LBLuca Bianchi
Luca Bianchi
Introduction: Seborrheic dermatitis is a common skin disease with clinical aspects similar to those of psoriasis, eczema or allergic reactions, appearing on the sebum-rich areas of the scalp, face, and trunk. Yeast like Malassezia species, immunologic abnormalities and activation of complement are recognized as a crucial pathogen for the onset of seborrheic dermatitis. Intermittent and active phases are characterized by burning, scaling and itching, then followed by inactive periods. The disease is sometimes severe up to the erythrodermia; thus, it has a great influence on the patient’s quality of life. In vitro and vivo studies have shown that the exogenous intake of glutathione-GSH-C4 and tocopherol inhibits lipid peroxidation and effectively fights and reduces oxidative stress in inflammatory disorders. Methods: We have carried out a study enrolling 20 patients affected by SD to evaluate the effectiveness and tolerability of a new topical formulation in cream (hereinafter SEB) containing GSH-C4 0.4% in hyaluronic acid 0.25% – a new synthetic glutathione derivate called INCI (butyroyl glutathione)-assigned by the Personal Care Council. Investigator Global Assessment score and Patient Global Assessment of Treatment scales were used to test the efficacy of this new formulation. Results: All patients showed a good clinical response to the treatment with topical SEB demonstrated by the gradual reduction in inflammatory skin lesions. Discussion: The results of our pilot study confirm the efficacy and tolerability of this new topical formulation in a real-life assessment and patients showed strong adherence to therapy. These promising results – still to be confirmed on a larger number of patients – emphasize the potential SEB has in controlling the chronic inflammation of seborrheic dermatitis.

26 May 2022 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
VGVirginia Garofalo
Virginia Garofalo
FGFrancesco Geraci
Francesco Geraci
MPMonia Di Prete
Monia Di Prete
CLCaterina Lanna
Caterina Lanna
FLFlavia Lozzi
Flavia Lozzi
Elena CampioneElena Campione
Elena Campione
Actinic keratosis is one of the most common dermatological disorders. A new topical solution, constituted by 0.5% 5-fluorouracil and 10% salicylic acid (Actikerall, Almirall) has been introduced in...